File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong

TitleA 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong
Authors
Issue Date2007
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCP
Citation
International Journal of Clinical Practice, 2007, v. 61 n. 3, p. 403-410 How to Cite?
AbstractThere was no long-term clinical study on galantamine in Alzheimer's disease (AD) in the Asian population. The objectives of this study were to evaluate the efficacy of galantamine on cognitive function, daily functioning, behavioural symptoms and its safety in Chinese AD patients. This was a 2-year open-label clinical trial. The inclusion criteria were patients with probable AD by the NINCDS-ADRDA criteria. A historical control group (n = 19) of AD patients with no galantamine or other cholinesterase inhibitor therapy was employed. In the galantamine group, 33 and 32 subjects had completed a 1-year and 2-year follow up, respectively. Within the galantamine group and at a 6-month follow up, the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog score) showed an improvement of 2.9 +/- 1.18 (p = 0.019, paired t-test) but remained the same at 1 and 2 years. The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) deteriorated by 4.31 +/- 2.06 (p = 0.044, paired t-test) at 6 months but showed no significant decline at 1 and 2 years vs. baseline. The Neuropsychiatric Inventory (NPI) score also showed a significant deterioration of 5 +/- 1.99 (p = 0.017, paired t-test) at 6 months, 8.06 +/- 1.97 (p < 0.001, paired t-test) at 1 year and 7.31 +/- 1.76 at 2 years. Comparison between the two groups showed a statistically significant improvement in the 1-year ADAS-cog score but decline in the NPI score in the galantamine vs. control groups. Adverse effects were commonly mild. In Chinese mild-moderate AD patients, galantamine showed beneficial effects mainly on the cognitive function.
Persistent Identifierhttp://hdl.handle.net/10722/213616
ISSN
2015 Impact Factor: 2.226
2015 SCImago Journal Rankings: 0.759

 

DC FieldValueLanguage
dc.contributor.authorChu, LW-
dc.contributor.authorYik, PY-
dc.contributor.authorMok, W-
dc.contributor.authorChung, CP-
dc.date.accessioned2015-08-07T02:49:05Z-
dc.date.available2015-08-07T02:49:05Z-
dc.date.issued2007-
dc.identifier.citationInternational Journal of Clinical Practice, 2007, v. 61 n. 3, p. 403-410-
dc.identifier.issn1368-5031-
dc.identifier.urihttp://hdl.handle.net/10722/213616-
dc.description.abstractThere was no long-term clinical study on galantamine in Alzheimer's disease (AD) in the Asian population. The objectives of this study were to evaluate the efficacy of galantamine on cognitive function, daily functioning, behavioural symptoms and its safety in Chinese AD patients. This was a 2-year open-label clinical trial. The inclusion criteria were patients with probable AD by the NINCDS-ADRDA criteria. A historical control group (n = 19) of AD patients with no galantamine or other cholinesterase inhibitor therapy was employed. In the galantamine group, 33 and 32 subjects had completed a 1-year and 2-year follow up, respectively. Within the galantamine group and at a 6-month follow up, the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog score) showed an improvement of 2.9 +/- 1.18 (p = 0.019, paired t-test) but remained the same at 1 and 2 years. The Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) deteriorated by 4.31 +/- 2.06 (p = 0.044, paired t-test) at 6 months but showed no significant decline at 1 and 2 years vs. baseline. The Neuropsychiatric Inventory (NPI) score also showed a significant deterioration of 5 +/- 1.99 (p = 0.017, paired t-test) at 6 months, 8.06 +/- 1.97 (p < 0.001, paired t-test) at 1 year and 7.31 +/- 1.76 at 2 years. Comparison between the two groups showed a statistically significant improvement in the 1-year ADAS-cog score but decline in the NPI score in the galantamine vs. control groups. Adverse effects were commonly mild. In Chinese mild-moderate AD patients, galantamine showed beneficial effects mainly on the cognitive function.-
dc.languageeng-
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IJCP-
dc.relation.ispartofInternational Journal of Clinical Practice-
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subject.meshAlzheimer Disease - drug therapy - ethnology-
dc.subject.meshChina - ethnology-
dc.subject.meshCholinesterase Inhibitors - adverse effects - therapeutic use-
dc.subject.meshGalantamine - adverse effects - therapeutic use-
dc.subject.meshNootropic Agents - adverse effects - therapeutic use-
dc.titleA 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong-
dc.typeArticle-
dc.identifier.doi10.1111/j.1742-1241.2007.01284.x-
dc.identifier.pmid17313606-
dc.identifier.scopuseid_2-s2.0-33847080422-
dc.identifier.hkuros137601-
dc.identifier.volume61-
dc.identifier.issue3-
dc.identifier.spage403-
dc.identifier.epage410-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats